Source link : https://www.newshealth.biz/health-news/sglt1-2-inhibitor-cut-stroke-heart-attack-risk-in-diabetic-kidney-disease/
(MedPage Today) — The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular risk factors, a prespecified… Source link : https://www.medpagetoday.com/nephrology/generalnephrology/114239 Author : Publish date : 2025-02-14 23:30:00 Copyright for syndicated content belongs to the linked […]
Author : News Health
Publish date : 2025-02-14 23:30:00
Copyright for syndicated content belongs to the linked Source.